Feb 24, 2016
Advancement in the understanding of Gastric Cancer was achieved in a study published last week at the Oncotarget Journal by investigators from BioGenex, the Stony Brooks University in NY and Soochow University in China. The study investigated the contribution of MicroRNAs (miRNAs) to Gastric Cancer growth and metastasis. Gastric cancer is the fifth most common malignancy and the third leading cause of cancer-related deaths. Despite the treatment progress and research efforts in gastric cancer, the outcome of patients with stage IV disease remains disappointing, with a 5-year overall survival rate of 4%.
The discovery of miRNAs has been one of the defining developments in cancer biology over the past decade. miRNAs are small, non-coding RNAs that regulate gene expression and have fundamental roles in Cancer growth and metastasis. In this study, researchers systematically investigated the roles of miRNA on a gene named Bmi-1, which is highly expressed in many tumors, including gastric cancer. The study found that miR-15a regulates the protein expression levels of Bmi-1 in gastric cancer. High levels of Bmi-1 in gastric cancer patients were significantly associated with better overall survival. The favorable outcome of gastric cancer patients with high levels of Bmi-1 may be due to the fact that these gastric tumor cells are highly sensitive to chemotherapy. Another possibility is that high levels of Bmi-1 are crucial in blocking metastatic process of advance stage gastric tumor in vivo.
“We are truly excited about these findings. The phenotypic correlation found in this study using 352 gastric cancer patients is very promising and may be used in the near future to develop diagnostic and prognostic tests for gastric cancer so we can make a significant impact on patient’s lives “ says Dr. Krish Kalra, BioGenex CEO. BioGenex is leading the miRNA revolution with the most advanced miRNA solutions and the broadest portfolio of miRNA In Situ Hybridization (ISH) probes (>200), ISH detection system and affordable automation platforms for clinical research and tumor analysis.
BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of CUP and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully-automated molecular pathology workstations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life Science research and diagnostics.